Intraoperative vasoplegia: Methylene blue to the rescue!

Current Opinion in Anaesthesiology

Volumn 31, Issue 1, 2018, Pages 43-49

  McCartney, Sharon L ^a   Duce, Lorent ^b   Ghadimi, Kamrouz ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiac surgery; Cardiopulmonary bypass; Methylene blue; Nitric oxide; Vasoplegia

Indexed keywords

METHYLENE BLUE;

ADVERSE EVENT; ANAPHYLAXIS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEART SURGERY; HUMAN; LIVER TRANSPLANTATION; META ANALYSIS (TOPIC); PEROPERATIVE CARE; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPTIC SHOCK; VASOPLEGIA; CARDIOPULMONARY BYPASS; DRUG EFFECT; VASCULAR RESISTANCE;

CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; HUMANS; LIVER TRANSPLANTATION; METHYLENE BLUE; VASCULAR RESISTANCE; VASOPLEGIA;

EID: 85041627919     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0000000000000548     Document Type: Review

References (53)

1. Gomes WJ, Carvalho AC, Palma JH, et al. Vasoplegic syndrome: A new dilemma. J Thorac Cardiovasc Surg 1994; 107: 942-943.
2. Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004; 77: 496-499.
3. Omar S, Zedan A, Nugent K. Cardiac vasoplegia syndrome: Pathophysiology, risk factors and treatment. Am J Med Sci 2015; 349: 80-88.
4. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345: 588-595.
5. Liu H, Yu L, Yang L, Green MS. Vasoplegic syndrome: An update on perioperative considerations. Journal of clinical anesthesia 2017; 40: 63-71.
6. Euroscore Interactive Calculator 2011. Available from: Http://www.euroscore. org/calc.html. [9 September 2017]
7. Evora PR, Ribeiro PJ, de Andrade JC. Methylene blue administration in SIRS after cardiac operations. Ann Thorac Surg 1997; 63: 1212-1213.
8. Evora PR. Should methylene blue be the drug of choice to treat vasoplegias caused by cardiopulmonary bypass and anaphylactic shock? J Thorac Cardiovasc Surg 2000; 119: 632-634.
9. Faber P, Ronald A, Millar BW. Methylthioninium chloride: Pharmacology and clinical applications with special emphasis on nitric oxide mediated vasodilatory shock during cardiopulmonary bypass. Anaesthesia 2005; 60: 575-587.
10. Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol 1993; 45: 367-374.
11. Pasin L, Umbrello M, Greco T, et al. Methylene blue as a vasopressor: A metaanalysis of randomised trials. Crit Care Resusc 2013; 15: 42-48.
12. Ghadimi K, Levy JH, Welsby IJ. Perioperative management of the bleeding patient. Br J Anaesth 2016; 117(Suppl 3): Iii18-iii30.
13. Corral-Velez V, Lopez-Delgado JC, Betancur-Zambrano NL, et al. The inflammatory response in cardiac surgery: An overview of the pathophysiology and clinical implications. Inflamm Allergy Drug Targets 2015; 13: 367-370.
14. Fischer GW, Levin MA. Vasoplegia during cardiac surgery: Current concepts and management. Semin Thorac Cardiovasc Surg 2010; 22: 140-144.
15. Gomes WJ, Carvalho AC, Palma JH, et al. Vasoplegic syndrome after open heart surgery. J Cardiovasc Surg (Torino) 1998; 39: 619-623.
16. Yiu P, Robin J, Pattison CW. Reversal of refractory hypotension with singledose methylene blue after coronary artery bypass surgery. J Thorac Cardiovasc Surg 1999; 118: 195-196.
17. Pagni S, Austin EH. Use of intravenous methylene blue for the treatment of refractory hypotension after cardiopulmonary bypass. J Thorac Cardiovasc Surg 2000; 119: 1297-1298.
18. Leyh RG, Kofidis T, Struber M, et al. Methylene blue: The drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? J Thorac Cardiovasc Surg 2003; 125: 1426-1431.
19. Maslow AD, Stearns G, Butala P, et al. The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass. Anesth Analg 2006; 103: 2-8. (table of contents).
20. Ozal E, Kuralay E, Yildirim V, et al. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg 2005; 79: 1615-1619.
21. Mazzeffi M, Hammer B, Chen E, et al.Methylene blue for postcardiopulmonary bypass vasoplegic syndrome: A cohort study. Ann Card Anaesth 2017; 20: 178-181.
22. Viaro F, Dalio MB, Evora PR. Catastrophic cardiovascular adverse reactions to protamine are nitric oxide/cyclic guanosine monophosphate dependent and endothelium mediated: Should methylene blue be the treatment of choice? Chest 2002; 122: 1061-1066.
23. Del Duca D, Sheth SS, Clarke AE, et al. Use of methylene blue for catecholamine- refractory vasoplegia from protamine and aprotinin. Ann Thorac Surg 2009; 87: 640-642.
24. Albuquerque AA, Margarido EA, Menardi AC, et al. Methylene blue to treat protamine-induced anaphylaxis reactions. An experimental study in pigs. Braz J Cardiovasc Surg 2016; 31: 226-231.
25. Weiner MM, Lin HM, Danforth D, et al. Methylene blue is associated with poor outcomes in vasoplegic shock. J Cardiothorac Vasc Anesth 2013; 27: 1233-1238.
26. Koelzow H, Gedney JA, Baumann J, et al. The effect of methylene blue on the hemodynamic changes during ischemia reperfusion injury in orthotopic liver transplantation. Anesth Analg 2002; 94: 824-829. (table of contents).
27. Fukazawa K, Pretto EA. The effect of methylene blue during orthotopic liver transplantation on post reperfusion syndrome and postoperative graft function. J Hepatobiliary Pancreat Sci 2011; 18: 406-413.
28. Cheng SS, Berman GW, Merritt GR, et al. The response to methylene blue in patients with severe hypotension during liver transplantation. J Clin Anesth 2012; 24: 324-328.
29. Cao Z, Gao Y, Tao G. Vasoplegic syndrome during liver transplantation. Anesth Analg 2009; 108: 1941-1943.
30. Vilalva KH, Mumic FT, Silveira MR, et al. Use of methylene blue to treat hypovolemic shock followed by ischemia-reperfusion injury in the postoperative orthotopic liver transplant patient: A case report. Exp Clin Transplant 2016; Aug 24. doi: 10.6002/ect.2016.0041. [Epub ahead of print]
31. Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: Summary report-second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med 2006; 47: 373-380.
32. Evora PR, Simon MR. Role of nitric oxide production in anaphylaxis and its relevance for the treatment of anaphylactic hypotension with methylene blue. Ann Allergy Asthma Immunol 2007; 99: 306-313.
33. Yuan Y, Granger HJ, Zawieja DC, et al. Histamine increases venular permeability via a phospholipase C-NO synthase-guanylate cyclase cascade. Am J Physiol 1993; 264(5 Pt 2): H1734-H1739.
34. Weissgerber AJ. Methylene blue for refractory hypotension: A case report. AANA J 2008; 76: 271-274.
35. Bauer CS, Vadas P, Kelly KJ. Methylene blue for the treatment of refractory anaphylaxis without hypotension. Am J Emerg Med 2013; 31: 264.e3-5.
36. Evora PR. Methylene blue for the treatment of refractory anaphylaxis without hypotension. Am J Emerg Med 2013; 31: 753.
37. Brown G, Frankl D, Phang T. Continuous infusion of methylene blue for septic shock. Postgrad Med J 1996; 72: 612-614.
38. Preiser JC, Lejeune P, Roman A, et al. Methylene blue administration in septic shock: A clinical trial. Crit Care Med 1995; 23: 259-264.
39. Donati A, ContiG, Loggi S, et al. Does methylene blue administration to septic shock patients affect vascular permeability and blood volume? Crit Care Med 2002; 30: 2271-2277.
40. Belletti A, Musu M, Silvetti S, et al. Non-adrenergic vasopressors in patients with or at risk for vasodilatory shock. A systematic review and meta-analysis of randomized trials. PloS One 2015; 10: E0142605.
41. Paciullo CA, McMahon Horner D, Hatton KW, Flynn JD. Methylene blue for the treatment of septic shock. Pharmacotherapy 2010; 30: 702-715.
42. Juffermans NP, Vervloet MG, Daemen-Gubbels CR, et al. A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock. Nitric Oxide 2010; 22: 275-280.
43. Evora PR, Alves Junior L, Ferreira CA, et al. Twenty years of vasoplegic syndrome treatment in heart surgery. Methylene blue revised. Rev Bras Cir Cardiovasc 2015; 30: 84-92.
44. Mehaffey JH, Johnston LE, Hawkins RB, et al. Methylene blue for vasoplegic syndrome after cardiac operation: Early administration improves survival. Ann Thorac Surg 2017; 104: 36-41.
45. Gachot B, Bedos JP, Veber B, et al. Short-term effects of methylene blue on hemodynamics and gas exchange in humans with septic shock. Intensive Care Med 1995; 21: 1027-1031.
46. Weingartner R, Oliveira E, Oliveira ES, et al. Blockade of the action of nitric oxide in human septic shock increases systemic vascular resistance and has detrimental effects on pulmonary function after a short infusion of methylene blue. Braz J Med Biol Res 1999; 32: 1505-1513.
47. Dumbarton TC, Gorman SK, Minor S, et al. Local cutaneous necrosis secondary to a prolonged peripheral infusion of methylene blue in vasodilatory shock. Ann Pharmacother 2012; 46: E6.
48. Sidi A, Paulus DA, Rush W, et al. Methylene blue and indocyanine green artifactually lower pulse oximetry readings of oxygen saturation. Studies in dogs. J Clin Monit 1987; 3: 249-256.
49. PROVAYBLUE (methylene blue) injection, for intravenous use. Initial U.S. Approval: 2016. 2016 [9 September 2017]. Available from: Https://http://www.accessdata.fda.gov/drugsatfda-docs/label/2016/204630s000lbl.pdf.
50. Hencken L, To L, Ly N, Morgan JA. Serotonin syndrome following methylene blue administration for vasoplegic syndrome. J Card Surg 2016; 31: 208-210.
51. Martino EA, Winterton D, Nardelli P, et al. The blue coma: The role of methylene blue in unexplained coma after cardiac surgery. J Cardiothorac Vasc Anesth 2016; 30: 423-427.
52. FDA Drug Safety Communication: Updated information about the drug interaction between methylene blue (methylthoninium chloride) and serotonergic psychiatric medications 2011. Available from: Https://http://www.fda.- gov/drugs/drugsafety/ucm276119.htm. [9 September 2017]
53. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med 2017; 43: 304-377.